Tretinoin lotion - Valeant Pharmaceuticals

Drug Profile

Tretinoin lotion - Valeant Pharmaceuticals

Alternative Names: IDP 121

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Valeant Pharmaceuticals International
  • Class Antiacnes; Antineoplastics; Keratolytics; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acne vulgaris

Most Recent Events

  • 16 Mar 2017 Valeant Pharmaceuticals announces intention to submit application to regulatory body for Acne vulgaris in 2017 (Valeant Pharmaceuticals pipeline, March 2017)
  • 01 Oct 2016 Valeant Pharmaceuticals completes a phase I trial in Acne vulgaris (In adolescents, In children) in USA (NCT02849860)
  • 26 Aug 2015 Valeant Pharmaceuticals plans a phase III trial for Acne in USA (NCT02535871)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top